CF PHARMTECH(02652): CF017 has submitted an application for listing approval in the Southeast Asian market.

CF PHARMTECH (02652) announced that the group has recently submitted an application for the marketing approval of CF017 Budesonide Inhalation Suspension to the relevant drug regulatory agencies in Southeast Asia. CF017 was approved for marketing by the National Medical Products Administration of the People's Republic of China in May 2021 and has since been commercially available in the domestic market. The population in Southeast Asia is large and continuously growing, with increasing medical demands and a rising incidence of respiratory diseases, making it a market with great potential for high-quality inhalation formulations. The company believes that submitting the marketing approval application for CF017 in the Southeast Asian market signifies a new milestone in the group's global strategy to expand its international commercial layout.